Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label randomized clinical trial
JD Schoenfeld, GJ Hanna, VY Jo, B Rawal… - JAMA …, 2020 - jamanetwork.com
Importance Novel approaches are needed to improve outcomes in patients with squamous
cell carcinoma of the oral cavity. Neoadjuvant immunotherapy given prior to surgery and
combining programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte–associated
protein 4 (CTLA-4) immune checkpoint inhibitors are 2 strategies to enhance antitumor
immune responses that could be of benefit. Design, Setting, and Participants In this
randomized phase 2 clinical trial conducted at 1 academic center, 29 patients with untreated …
cell carcinoma of the oral cavity. Neoadjuvant immunotherapy given prior to surgery and
combining programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte–associated
protein 4 (CTLA-4) immune checkpoint inhibitors are 2 strategies to enhance antitumor
immune responses that could be of benefit. Design, Setting, and Participants In this
randomized phase 2 clinical trial conducted at 1 academic center, 29 patients with untreated …